Join Growin Stock Community!

Anbio biotechnology class a ordinary sharesNNNN.US Overview

US StockHealthcare
(No presentation for NNNN)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

NNNN AI Insights

NNNN Overall Performance

NNNN AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

NNNN Recent Performance

-10.68%

Anbio biotechnology class a ordinary shares

0.05%

Avg of Sector

-0.31%

S&P500

NNNN PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

NNNN Key Information

NNNN Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

NNNN Profile

Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, Africa, and internationally. It offers SARS-CoV-2 antigen rapid and SARS-CoV-2/influenza A/B antigen rapid tests; and lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, chemiluminescence immunoassay, and reverse-transcription polymerase chain reaction products. It serves over-the-counter, point-of-care testing, and laboratory markets. The company was incorporated in 2021 and is based in Frankfurt am Main, Germany.

Price of NNNN

NNNN FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

NNNN Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
0.06
PE Ratio (TTM)
429.33
Forward PE
-
PS Ratio (TTM)
163.38
PB Ratio
44.58
Price-to-FCF
446.51
METRIC
VALUE
vs. INDUSTRY
Gross Margin
71.91%
Net Margin
28.95%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
0.06
PE Ratio (TTM)
429.33
Forward PE
-
PS Ratio (TTM)
163.38
PB Ratio
44.58
Price-to-FCF
446.51
Gross Margin
71.91%
Net Margin
28.95%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is NNNN's latest earnings report released?

    The most recent financial report for Anbio biotechnology class a ordinary shares (NNNN) covers the period of 2024Q4 and was published on 2024/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating NNNN's short-term business performance and financial health. For the latest updates on NNNN's earnings releases, visit this page regularly.

  • How much cash does NNNN have?

    At the end of the period, Anbio biotechnology class a ordinary shares (NNNN) held Total Cash and Cash Equivalents of 11.76M, accounting for 0.62 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does NNNN go with three margins increasing?

    In the latest report, Anbio biotechnology class a ordinary shares (NNNN) did not achieve the “three margins increasing” benchmark, with a gross margin of 84.55%%, operating margin of -68.64%%, and net margin of -52.4%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess NNNN's profit trajectory and future growth potential.

  • What are the PEG ratio and PE ratio of NNNN?

    The latest valuation data shows Anbio biotechnology class a ordinary shares (NNNN) has a Price-To-Earnings (PE) ratio of -46.05 and a Price/Earnings-To-Growth (PEG) ratio of 0.34. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.